All News

The passage of MMA changed the oncology practice landscape, now we’re entering into unknown territory with Obama’s reform bill. Voice your opinions/perspectives on practice and policy issues affecting cancer care with 35,000 of your colleagues on the pages of ONCOLOGY.

We cannot escape the realities of biology. Just as children rescued from leukemia and lymphoma live to grow into adults who must confront the adverse effects of their curative treatment, people rescued from AIDS by HAART (highly active antiretroviral therapy) are showing a substantially increased risk of cancers other than the "AIDS-defining" malignancies designated by the Centers for Disease Control in the 1980s: Kaposi sarcoma, non-Hodgkin lymphoma (NHL), and cervical cancer.

The government is providing time-sensitive incentives to drive EHR adoption. There's a lot to learn, let's get started.

Yoga, first described in the Vedic texts of India, has been practiced for millennia. It involves regulated breathing, moving through various postures known as asanas, and meditation, aimed at achieving physical and psychological well-being. Many styles of yoga encompass some or all of these components. Yoga can have a positive impact on quality of life (QOL) in people with and without cancer, by reducing stress and fatigue and improving symptoms of certain inflammatory conditions. In the cancer setting alone, there are at least 10 randomized trials documenting the benefits of yoga on patients’ QOL.

The treatment of cancer of the anal canal has changed significantly over the past several decades. Although the abdominoperineal resection (APR) was the historical standard of care, a therapeutic paradigm shift occurred with the seminal work of Nigro, who reported that anal canal cancer could be treated with definitive chemoradiation, with APR reserved for salvage therapy only. This remains an attractive approach for patients and physicians alike and the standard of care in this disease. Now, nearly four decades later, a similar approach continues to be utilized, albeit with higher radiation doses; however, this strategy remains fraught with considerable treatment-related morbidities. With the advent of intensity-modulated radiation therapy (IMRT), many oncologists are beginning to utilize this technology in the treatment of anal cancer in order to decrease these toxicities while maintaining similar treatment efficacy. This article reviews the relevant literature leading up to the modern treatment of anal canal cancer, and discusses IMRT-related toxicity and disease-related outcomes in the context of outcomes of conventionally treated anal cancer.

Complications of the bone remain a major clinical problem in oncology, resulting in significant morbidity and increased risk of death.

Although the use of bisphosphonates is a well-established form of supportive care treatment for bone metastasis, complications arising from long-term use require schedule optimization and a search for alternative strategies.

Early data from an ongoing randomized trials in the UK strongly suggest that denosumab might play a defined role in the future management of metastatic bone disease.

The exodus of doctors from Medicare and likely from private practice altogether - is accelerating.

A Seattle cancer center appoints a new leader while ASCO bestows development awards on international researchers. Learn more about the latest appointments and accolades in the cancer community.

The Ohio State University Comprehensive Cancer Center–Authur G. James Cancer Hospital and Richard J. Solove Research Institution (OSUCCC-James) has begun construction on a 276-bed cancer facility.

Clinical studies examining the potential of CT exposure to cause cancer are under way, but it could be years or even a decade until the results are known, and even then, they may be inconclusive.

There was a time when a cancer diagnosis meant long commutes for patients in small communities and rural America. The kind of care they needed was available only at tertiary medical centers, typically in metropolitan areas. An expanded network of community cancer clinics changed that, providing convenience and comfort for many thousands of patients. A few years ago those centers were treating four out of five U.S. cancer patients. But now this net of care providers is collapsing under the weight of falling Medicare reimbursement.

IndicationNplate® is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

Whether elderly patients receive adjuvant therapy depends on their health status and how well the physician communicates the risks and benefits.

Glut of e-health information has put public in a ‘data smog.’

Data from French trial should inform treatment decisions in the majority of lung cancer patients aged 70 and up.

Nplate® is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Nplate® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.

body { color: #000000; /* color: #002F65; */ background-color:#f5f5f5; } table { background-color:#FFFFFF; text-align:left; font-family: Tahoma, Verdana, Arial, Helvetica, sans-serif; font-size: 12px; line-height: normal; font-weight: normal; } p, div { font-family: Tahoma, Verdana, Arial, Helvetica, sans-serif; font-size: 12px; line-height: normal; font-weight: normal; } h3 { font-family: Tahoma, Verdana, Arial, Helvetica, sans-serif; font-size: 12px; line-height: normal; font-weight:bold; } a { color:#3e7ebc; } a:hover { text-decoration:underline } p { margin:10px 0px 10px 0px; } ol, ul{ list-style: none; padding-left:0px; } .header-link { font-size: 13px; font-weight: bold; color: #C41230; text-decoration:none } .mainbody { font-family: Tahoma, Verdana, Arial, Helvetica, sans-serif; font-size: 12px; line-height: normal; font-weight: normal; padding: 10px 30px 10px 30px; } .otherbody { font-family: Tahoma, Verdana, Arial, Helvetica, sans-serif; font-size: 12px; line-height: normal; font-weight: normal; color: #000000; } .blue-link { color: #002F65; text-decoration: underline; } .blue-bold-link { color: #002F65; text-decoration: underline; font-size: 13px; font-weight: bold; } .red-header { font-size: 13px; font-weight: bold; color: #C41230; } .smbullet-item { background-image:url(sm-bullet.gif); } .bullet-item { background-color: transparent; background-image: url("http://imaging.ubmmedica.com/all/cn/infocenter/chronic-itp/bullet.gif"); background-repeat: no-repeat; background-attachment: scroll; background-position: 0pt 2px; padding-top: 0pt; padding-right: 0pt; padding-bottom: 15px; padding-left: 20px; margin-bottom: 12px; margin-left:25px } li { list-style:disc; padding-top: 0pt; padding-right: 0pt; padding-bottom: 5px; padding-left: 5px; margin-bottom: 0px; margin-left:25px } #bulletItems li { list-style: none; background-color: transparent; background-image: url("http://imaging.ubmmedica.com/all/cn/infocenter/chronic-itp/bullet.gif"); background-repeat: no-repeat; background-attachment: scroll; background-position: 0pt 5px; padding-top: 0pt; padding-right: 0pt; padding-bottom: 5px; padding-left: 20px; margin-bottom: 0px; margin-left:15px } #bulletItems p, .tan { color: #E8D4A3 } .resBox { width: 250px; border-left-width-value: 1px; border-left-style-value: solid; border-left-color-value: #d3d3d3; border-right-width-value: 1px; border-right-style-value: solid; border-right-color-value: #d3d3d3; padding-top: 0px; padding-right: 10px; padding-bottom: 0px; padding-left: 10px; text-align: left; word-wrap: break-word; } #wrapper { width:100%; padding:0px; margin:0px; text-align:center; } /************************ ***** DO NOT EDIT ******/#container { /*width: 80%;*/ width: 300px; margin-right: auto; margin-left: auto; text-align: left; background-color: #FFFFFF;}/* Bar Graphs */.graph { width: 280px; position: relative; right: 16px;}.bar-title { position: relative; float: left; width: 140px; line-height: 20px; margin-right: 12px; font-weight: bold; text-align: right; color: #C41230;}.bar-container { position: relative; float: left; width: 120px; height: 10px; margin: 0px 0px 15px;}.bar-container div { background-color:#c61130; height: 20px;}.bar-container strong { position: absolute; right: 0; top: 0px; overflow: hidden;}#poll-results p { clear: both; text-align: center;}#poll-container { font-family: Tahoma, Verdana, Arial, Helvetica, sans-serif; font-size:11px; background: #ffffff url(/blank-theme/images/custom/poll-bg-top.png) 0 0 no-repeat; padding: 16px 24px 16px 16px; line-height: 14px;}#poll-bottom { height: 12px; width: 300px; background: #ffffff url(/blank-theme/images/custom/poll-bg-bottom.png) bottom left no-repeat;}#poll-container input { margin: 8px 4px 0;}#poll-container label { color: #C41230; font-weight: bold;}#poll-container p { color: black; line-height: 20px; padding-top: 5px; padding-right: 5px; padding-bottom: 5px; padding-left: 5px;}#poll-container h3 { margin: 8px;}input#pollbutton { width: 78px; height: 30px; float: right; margin: 10px -4px -10px 0; border: 0 none; cursor: pointer; display: inline; background: transparent url(/blank-theme/images/custom/poll-button.png) top left no-repeat;}/***************************** END DO NOT EDIT *****/

As more doctors turn to fluconazole for empirical antifungal therapy, some of the weakest patients--those with hematological malignancies and neutropenia--are most likely to pay the price, succumbing to resistant microorganisms.

We are pleased to announce that internationally regarded radiation oncologist, Nora Janjan, MD, Editor-in-Chief of ONCOLOGY, will parlay her policy expertise and serve as Editor for the journal’s new Practice & Policy department set to launch in the September edition.

A 2-day meeting on the impact of Risk Evaluation & Mitigation Strategies (REMS) kicked off with feedback from a provider group, which expressed a desire for more input by outside stakeholders on the development of specific REMS.

Indication Nplate® is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

Paper records are soon to be a thing of the past, like it or not. Check out this one-stop guide to help you navigate the murky waters of government-mandated electronic healthcare records: Supplied by Physician’s Practice.

Four months after House Speaker Nancy Pelosi declared “We have to pass the bill so you can find out what’s in it,” a congressional panel has released the first chart illustrating the 2,801 page health care law President Obama signed into law in March. Check out the video…

In this video interview, Oncology board member and CancerNetwork contributing editor, Derek Raghavan, MD, PhD, Institute Chair, Taussig Cancer Institute gives his opinion on how the changing landscape of the American healthcare system will affect cancer care.